Why Attend the 8th RNAi-Based Therapeutics Summit?
The RNAi field is entering a new era of growth driven by significant investment, major partnerships and expanding clinical success.
With high-profile deals including Sanegene Bio & Genentech for up to $1.5bn and Novartis’ acquisition of Avidity Bioscience, and quiet confidence building into this space – the time is now for the RNAi community.
At the 8th RNAi-Based Therapeutics Summit, join the only industry dedicated forum uniting C-suite leaders and Directors working across oligo synthesis and chemistry, biology and molecular design to showcase the latest advances in antibody-oligonucleotide conjugates, nanoparticles, and other next-generation targeting technologies.
This is your one-stop shop to learn how to improve targeted delivery to a greater range of disease areas whilst balancing safety and efficacy.
Event Highlights
Advance Extrahepatic RNAi Delivery
Gain practical insights to how your peers are overcoming delivery barriers and expanding RNAi therapeutics into high-value tissues including the CNS, skeletal muscle, retina, kidney and adipose tissue.
With expert insights from:
Paul Lawrence, Executive Director, Bioscience Research, Biocogent
Explore Next-Generation Delivery Technologies
Benchmark the latest delivery platforms, from aptamer-siRNA conjugates to tetravalent siRNAs and centyrin-based systems, to identify the most promising approaches for your pipeline.
With expert insights from:
Claudio Punzo, Co-Founder & Chief Scientific Officer, Trinetra Therapeutics
Thomas Ormsby, Postdoctoral Associate, UMass Chan Medical School
Katherine Palozola, Senior Principal Investigator, Aro Biotherapeutics
Expand into New Disease Areas
Discover how innovators are successfully applying RNAi across obesity, cardiovascular disease, retinal disorders, kidney disease and oncology to identify your next therapeutic opportunity.
With expert insights from:
Crystal Jin, Co-Founder & Chief Executive Officer, Bound Therapeutics
Diego Piqueras-Losilla, Research & Development Project Leader, ARTHEx Biotech
Improve RNAi Chemistry & Durability
Learn how advances in oligonucleotide chemistry, PK/PD optimisation and endosomal escape are improving potency, durability and safety to create more competitive RNAi medicines.
With expert insights from:
Julia Alterman, Assistant Professor, UMass Chan Medical School
Jimmy Weterings, Vice President & Head of Oligonucleotide Therapeutics, Bonito Biosciences
Pooja Gangras, Director, Molecule Discovery & Technology Licensing, Eli Lilly and Company
Jihye Park, Associate Director, Novo Nordisk
Build Clinical & Commercial Success
Apply lessons from clinical-stage programs and industry leaders to de-risk development, strengthen your investment strategy and build valuable partnerships that move programs forward.
With Expert Insights from:
Soren Ottosen, Senior Scientific Director, Bayer
Michael Palfreyman, Non-Executive Director, Thalia Therapeutics
Raj Reddy, President, Founder & Chief Executive Officer, Canary Cure
Explore the Full Event Guide
- Learn from 20+ expert speakers from leading biotech and pharma companies including Eli Lilly, Bayer, Thalia Therapeutics, & Canary Cure
- Explore the newest insights into data covering extrahepatic RNAi delivery, CNS, cardiovascular, obesity, retinal & oncology applications, as well as applications of miRNA technology
- Gain practical insights into funding, partnerships & clinical translation strategies
- Create connections with top RNAi decision-makers through dedicated networking sessions with 80+ industry leaders
Attending Companies Include
Explore the Agenda
Discover the latest advances in extrahepatic delivery, RNAi chemistry, CNS targeting and chronic disease applications.
Partner With Us
Showcase your capabilities to RNAi developers seeking solutions for delivery, manufacturing and clinical translation.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.